Australian researchers have discovered that the TAK1 gene helps cancer cells survive attack from the immune system, revealing ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...

Inflammation has long been a warning sign in kidney clinics, a red flag that often appears years before a patient tips into ...

Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts ...

Scientists mapped hidden DNA switches in brain support cells to understand how gene control may influence Alzheimer’s disease ...

The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the development of ...

As the year draws to a close, we take a look at some of the biggest science stories of the year, and why they matter.

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

That’s because the industry veteran will join Alnylam’s board as of Jan. 5. Arbuckle had been executive vice president and ...

Ophidion, Inc., a biotechnology company pioneering non-invasive delivery of gene-silencing and large-molecule therapeutics to the brain, and Neuronasal, Inc., a clinical-stage company advancing ...

As of Tuesday, December 23, Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 9.52%, which has investors questioning if this is right time to buy.

Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...